Edwards Lifesciences Corporation (NYSE:EW) traded higher in the last at $99.19, gaining 0.03 points or 0.03%. From the data available, it can be said that the stock did not make an impact in the money flow department with the net figure coming to be $(-1.29) million. The composite uptick value of $2.61 million was eclipsed by the accrued downtick value of $3.9 million, thereby ensuring the up/down ratio of 0.67. For the week, the shares have posted returns of 0.66%.A block trade registered during the day has revealed $0 million in upticks and $1.15 million in downticks. The up/down ratio in this case turned out to be 0. The net money flow for the block trade was $(-1.15) million.
The stock has recorded a 20-day Moving Average of 1.89% and the 50-Day Moving Average is 4.77%. The company shares have rallied 37.12% in the past 52 Weeks. On April 27, 2016 The shares registered one year high of $112 and one year low was seen on August 24, 2015 at $62.53. The 50-day moving average is $101.82 and the 200 day moving average is recorded at $90.88. S&P 500 has rallied 1.93% during the last 52-weeks.
Edwards Lifesciences Corporation (NYSE:EW): The stock opened at $99.44 on Tuesday but the bulls could not build on the opening and the stock topped out at $99.90 for the day. The stock traded down to $98.35 during the day, due to lack of any buying support eventually closed down at $98.57 with a loss of -0.60% for the day. The stock had closed at $99.16 on the previous day. The total traded volume was 1,246,992 shares.
Currently the company Insiders own 2.37% of Edwards Lifesciences Corporation shares according to the proxy statements. Institutional Investors own 87.59% of Edwards Lifesciences Corporation shares. On the companys insider trading activities, Mussallem Michael A, director officer (Chairman & CEO) of Edwards Lifesciences Corp, unloaded 49,100 shares at an average price of $102.25 on June 8, 2016. The total amount of the transaction was worth $5,020,475, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.